Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
- 1 March 2008
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 75 (6) , 1262-1271
- https://doi.org/10.1016/j.bcp.2007.10.016
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Investigation of the Lactam Side Chain Length Necessary for Optimal Indenoisoquinoline Topoisomerase I Inhibition and Cytotoxicity in Human Cancer Cell CulturesJournal of Medicinal Chemistry, 2007
- Compressing drug development timelines in oncology using phase '0' trialsNature Reviews Cancer, 2007
- A Systematic Study of Nitrated Indenoisoquinolines Reveals a Potent Topoisomerase I InhibitorJournal of Medicinal Chemistry, 2006
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen HeterocyclesJournal of Medicinal Chemistry, 2006
- Repair of Topoisomerase I‐Mediated DNA DamageProgress in Nucleic Acid Research and Molecular Biology, 2006
- Drug development in oncology: classical cytotoxics and molecularly targeted agentsBritish Journal of Clinical Pharmacology, 2006
- BN80927Cancer Research, 2004
- Transcription-Dependent Degradation of Topoisomerase I-DNA Covalent ComplexesMolecular and Cellular Biology, 2003
- DNA supercoiling and prokaryotic transcriptionCell, 1989